Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway

Archives of Physiology and Biochemistry

Volumn 122, Issue 4, 2016, Pages 186-194

  Al Rasheed, Nouf Mohamed ^a   Al Rasheed, Nawal Mohamed ^a,b   Al Amin, Maha Abdelrahman ^a   Hasan, Iman Huesein ^a   Al Ajmi, Hanaa Najeeb ^a   Mohammad, Raeesa Ahmed ^c   Attia, Hala Aboulfotooh ^a,d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b PRINCESS NOURAH BINT ABDULRAHMAN UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

Animals; antibody; diabetic nephropathy; drugs; fenofibrate; Smad3; TGF 1

Indexed keywords

ANTILIPEMIC AGENT; FENOFIBRATE; MADH3 PROTEIN, RAT; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; ENZYME IMMUNOASSAY; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FENOFIBRATE; GENE EXPRESSION REGULATION; HYPOLIPIDEMIC AGENTS; IMMUNOENZYME TECHNIQUES; MALE; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84962439016     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2016.1164186     Document Type: Article

References (46)

1. S.Adler. (1994). Structure-function-relationships associated with extracellular-matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol, 5:1165–72
2. American Diabetes Association (ADA). (2003). Diabetic nephropathy. Diabetes Care, 26:S94–8
3. V.G.Athyros, K.Tziomalos, A.Karagiannis, D.P.Mikhailidis. (2011). Dyslipidemia of obesity metabolic syndrome and type 2 diabetes mellitus:The case for residual risk reduction after statin treatment. Open Cardiovasc Med J, 5:24–34
4. L.Attisano, J.L.Wrana. (2002). Signal transduction by the TGF-beta superfamily. Science, 296:1646–7
5. P.Balakumar, V.A.Chakkarwar, M.Singh. (2009). Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem, 320:149–62
6. H.Bartels, M.Bohmer. (1972). Serum creatinine determination without protein precipitation. Clin Chem Acta, 37:193–7
7. D.E.Carling, C.S.Rothrock, G.C.MacNish,. (1994). Characterisation of anastomosis group 11 (AG-11) of Rhizoctonia solani. Phytopathology, 84:1387–93
8. H.Y.Chen, X.R.Huang, W.Wang,. (2011). The protective role of Smad7 in diabetic kidney disease:Mechanism and therapeutic potential. Diabetes, 60:590–601
9. L.L.Chen, J.Y.Zhang, B.P.Wang. (2006). Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vasc Pharmacol, 44:309–15
10. Y.J.Chen, J.Quilley. (2008). Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase expression and enhanced renal prostaglandin release. J Pharmacol Exp Therap, 324:658–63
11. B.T.Doumas, W.A.Watson, H.G.Biggs. (1971). Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta, 31:87–96
12. S.Fazio, M.F.Linton. (2010). High-density lipoprotein therapeutics and cardiovascular prevention. J Clin Lipidol, 4:411–9
13. L.B.Foster, J.M.Hochholzer. (1971). A single-reagent manual method for directly determining urea nitrogen in serum. Clin Chem, 17:921–5
14. E.Galkina, K.Ley. (2006). Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol, 17:368–77
15. G.Gilliland, S.Perrin, K.Blanchard, H.F.Bunn. (1990). Analysis of cytokine mRNA and DNA:Detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA, 87:2725–9
16. S.Goldfarb, F.N.Ziyadeh. (2001). TGF-beta:A crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc, 112:27–32
17. Y.Guan, M.D.Breyer. (2001). Peroxisome proliferator-activated receptors (PPARs):Novel therapeutic targets in renal disease. Kidney Int, 60:14–30
18. Z.S.Hakim, B.K.Patel, R.K.Goyal. (1997). Effects of chronic ramipril treatment in streptozotocin-induced diabetic rats. Indian J Physiol Pharmacol, 41:353–60
19. H.H.Hao, Z.M.Shao, D.Q.Tang,. (2012). Preventive effects of rutin on the development of experimental diabetic nephropathy in rats. Life Sci, 91:959–67
20. B.Hocher, C.Thöne-Reineke, P.Rohmeiss,. (1997). Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest, 99:1380–9
21. M.Isono, S.Chen, S.W.Hong,. (2002). Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun, 296:1356–65
22. S.Kadian, N.Mahadevan, P.Balakumar. (2013). Differential effects of low dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy. Eur J Pharmacol, 698:388–96
23. H.Kastarinen, O.Ukkola, Y.A.Kesäniemi. (2009). Glomerular filtration rate is related to carotid intima-media thickness in middle-aged adults. Nephrol Dial Transplant, 24:2767–72
24. I.Kouroumichakis, N.Papanas, P.Zarogoulidis,. (2012). Fibrates:Therapeutic potential for diabetic nephropathy? Eur J Int Med, 23:309–16
25. M.Lehir, W.Kriz. (2007). New insights into structural patterns encountered in glomerulosclerosis. Curr Opin Nephrol Hypertens, 16:184–91
26. L.Li, N.Emmett, D.Mann, X.Zhao. (2009). Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. Exp Biol Med (Maywood), 235:383–91
27. A.N.Long, S.Dagogo-Jack. (2011). Comorbidities of diabetes and hypertension:Mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich), 13:44–251
28. J.Manoj. (2012). Histopathological changes in diabetic kidney disease. Clin Queries Nephrol, 0102:127–33
29. S.M.Mauer. (1994). Structural-functional correlations of diabetic nephropathy. Kidney Int, 45:612–22
30. H.J.Milionis, M.S.Elisaf. (2000). Management of hypertension and dyslipidaemia in patients presenting with hyperuricemia:Case histories. Curr Med Res Opin, 16:164–70
31. C.Mora, J.F.Navarro. (2005). The role of inflammation as a pathogenic factor in the development of renal disease in diabetes. Curr Diab Rep, 5:399–401
32. A.Moustakas, C.H.Heldin. (2008). Dynamic control of TGF-beta signaling and its links to the cytoskeleton. FEBS Lett, 582:2051–65
33. C.W.Park, H.W.Kim, S.H.Ko,. (2006a). Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator activated receptor alpha. Diabetes, 55:885–93
34. C.W.Park, H.W.Kim, S.H.Ko,. (2006b). Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes, 55:885–93
35. C.W.Park, Y.Zhang, X.Zhang,. (2006c). PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int, 69:1511–7
36. P.Paueksakon, M.P.Revelo, L.J.Ma,. (2002). Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int, 61:2142–8
37. K.Sharma, T.A.Mc Gowan. (2000). TGF-beta in diabetic kidney disease:Role of novel signaling pathways. Cytokine Growth Factor Rev, 11:115–23
38. K.Sharma, F.N.Ziyadeh. (1995). Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes, 44:1139–46
39. J.R.Sowers, M.Epstein. (1995). Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension, 26:869–79
40. A.Tenenbaum, E.Z.Fisman. (2004). Which is the best lipid-modifying strategy in metabolic syndrome and diabetes:Fibrates, statins or both? Cardiovasc Diabetol, 3:10. doi:10.1186/1475-2840-3-10
41. N.M.Tietz. (1990). Clinical guide to laboratory test. 2nd edn. Philadelphia, PA:WB Saunders Co., 246–50
42. S.Wild, G.Roglic, A.Green,. (2004). Global prevalence of diabetes:Estimates for the year 2000 and projections for 2030. Diabetes Care, 27:1047–53
43. F.Yang, A.C.Chung, X.Ru Huang, H.Y.Lan. (2009). Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-{beta}-dependent and –independent Smad pathways. The role of Smad3. Hypertension, 54:877–84
44. T.Zelmanovitz, F.Gerchman, A.P.Balthazar,. (2009). Diabetic nephropathy. Diabetol Metab Syndr, 1:10. doi:10.1186/1758-5996-1-10
45. X.Zhao, L.Y.Li. (2008). PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol, 28:598–606
46. F.Ziyadeh, D.C.Han. (1997). Involvement of transforming growth factor-b and its re- 847 ceptors in the pathogenesis of diabetic nephropathy. Kidney Int, 52:848